Perumal J, et al. - Researchers performed this prespecified 2-year interim analysis of STRIVE—a multicenter, observational, open-label, single-arm study of natalizumab in anti–JC virus (JCV) seronegative patients with early relapsing-remitting multiple sclerosis (RRMS)—in order to assess the efficacy of natalizumab in establishing and maintaining no evidence of disease activity (NEDA) in early RRMS. The study population comprised 222 patients (aged 18–65 years) who had an RRMS diagnosis < 3 years prior to screening, an Expanded Disability Status Scale score ≤ 4.0, and anti-JCV antibody negative status. Outcomes supported the efficacy of natalizumab over 2 years, during which time NEDA was achieved in nearly half of early RRMS patients. NEDA was exhibited by nearly 75% of patients during year 2. Significant cognitive and quality-of-life benefits were noted among patients over 2 years.